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Abstract Endometriosis is a complex disease arising from
the interplay between multiple genetic and environmental
factors. The genetic variants potentially underlying the hered-
itary component of endometriosis have been widely investi-
gated through hypothesis-driven candidate gene studies, an
approach that generally has proven to be inherently difficult
and problematic for a number of reasons. Recently, through
major collaborative efforts in the endometriosis research field,
hypothesis-free genome-wide approaches have started to
provide new insights into potential pathways leading to devel-
opment of endometriosis, as well as highlighting the pheno-
typic heterogeneity of the condition. This review summarizes
the most recent studies investigating the genetic variation
contributing to endometriosis, with a particular focus on
genome-wide approaches, and discusses promising future
directions of genetic research.




Endometriosis is a common estrogen (E)-dependent gyneco-
logical disorder, characterized by presence of tissue resem-
bling endometrium tissue outside the uterine cavity. Typical
locationsfortheectopicdepositsareonthepelvicperitoneum,
the ovaries, uterosacral ligaments, pouch of Douglas, and the
rectovaginal septum. Endometriosis has been associated with
chronic pelvic pain, reduced fertility, and severe dysmenor-
rhea [1, 2]. Definitive diagnosis can only be established
through surgery, and, though other classifications exist, the
disease is most commonly staged using the revised American
Fertility Society (rAFS) classification, based on the total sur-
face size of the lesions, presence of adhesions, and ovarian
lesions [3]. Because endometriosis is E-dependent, it occurs
almostexclusivelyinwomenofreproductiveage[4].Because
of the need for surgical diagnosis, the exact population prev-
alence is unknown. Based on community prevalence rates of
pelvic pain and infertility, the prevalence of endometriosis is
estimated to be about 5–10 % in premenopausal women [5],
increasing to 35–50 % in women undergoing laparoscopy for
pelvic pain and infertility [1, 6].
The etiology of endometriosis remains unclear. The most
widelyacceptedmechanism for developmentofthe peritoneal
endometrioticlesionsisviaretrogrademenstruation[7].How-
ever, menstrual debris is present in the peritoneal cavity of up
to90% ofthe menstruatingwomen [8].Possibleexplanations
foradhesionandgrowthofendometrioticlesionsinonlysome
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increased menstrual flow, shorter cycle length), abnormal
eutopic endometrium, altered peritoneal environment, re-
duced immune surveillance, and increased angiogenic capac-
ity [9–11]. It is possible that several, if not all, of these factors
playaroletoanextent,and/orthatspecificsubtypesofdisease
are due to specific underlying biological pathways; research
continues to elucidate these mechanisms.
One approach to study the underlying biological pathways
leading to a complex disease such as endometriosis (the
development of which is determined by multiple genetic and
environmental factors)istostudythe effectofgenetic variants
on disease causation. The involvement of genetic factors in
the development of endometriosis is supported by different
studies [12–14]. Twin studies have shown increased concor-
dance in monozygotic twins when compared to dizygotic
twins[15,16];thelargestsuchstudycarriedouttodateamong
Australian 3,096 female twins concluded that about 51 % of
thevariationinendometriosisriskisheritable[16].Inaddition
to human studies, familial aggregation of spontaneous (i.e.,
non-induced) endometriosis also has been shown in nonhu-
man primates such as the rhesus macaque [17].
Studydesignstosearchforgenesunderlyingendometriosis
can be separated into hypothesis-based and hypothesis-free
approaches. Hypothesis-based “candidate gene” studies typi-
cally rely on prior biological hypotheses/knowledge of the
disease or of the approximate genomic location of a disease-
predisposing variant derived from a hypothesis-free study.
Hypothesis-free studies search the entire genome to identify
disease-predisposing variants, without knowledge of their
functional relevance. This review summarizes the evidence
from the most recent studies investigating the genetic varia-
tion contributing to endometriosis. Of particular focus will be
the results from large-scale collaborative genome-wide
approaches, which have started to provide new insights into
potential pathways leading to endometriosis.
Hypothesis-Based Research: Candidate Gene
Association Studies
Historically, the search of genes contributing to susceptibility
of many complex diseases such as endometriosis began with
hypothesis-driven “candidate gene association” studies
(CGASs). Although hypothesis-free approaches have since
taken off, candidate gene studies based on a biological
“hunch” alone are still commonplace. CGASs are based on
thea prioriselection ofgeneswithinferredbiologicalfunction
and association of variants in these genes with disease risk.
With limited budgets and faced with over 20,000 genes in the
human genome, the approach seems an attractive one. How-
ever, CGASs are inherently limited by current knowledge of
biological mechanisms underlying the studied phenotype,
which is attenuated in diseases where the underlying mecha-
nisms are not very well understood, such as in endometriosis.
Furthermore, to fully test the involvement of a biological
pathway, one would need to investigate all genes making up
the pathway (as well as factors regulating their expression), in
a large sample of cases and controls; a costly approach
that has, to our knowledge, never been adopted. Therefore,
the probability of success of a CGAS as commonly con-
ducted, based on the testing of a few, selected, variants in
a handful of genes, is extremely low. This probability may
be greatly improved if evidence of the likely genomic
location of a disease-predisposing variant, derived from a
whole genome linkage study for example, is included,
although this approach has its own drawbacks (described
later in this article).
Association studies these days typically focus on the most
abundant genetic variants in the genome: single nucleotide
polymorphisms (SNPs), which comprise over 90 % of all
common genetic variation in the human genome [18]. SNPs
are changes to the DNA at one nucleotide base pair, and can
have two identities, or “alleles.” Association studies compare
the frequency of the alleles of a genetic variant between cases
and controls, and can be of direct and indirect design. Direct
association studies aim to test specific genetic variants by
genotyping these, whereas indirect association studies type a
set of common (population allele frequency>0.05) SNPs
carefully selected on the basis of local genomic “linkage
disequilibrium” (LD). LD is the nonrandom association of
genetic variants in a population. This phenomenon means, in
simple terms, that an SNP can predict the status of a genetic
variant nearby because of common ancestry of that particular
genomic segment. The International HapMap Project [19]h a s
mappedLD patternsacrossthe human genomeina numberof
ethnic populations, which has enabled the investigation of
whole sections of the genome for their association with many
common complex diseases; by testing those SNPs that are
highly predictive of the status of other SNPs in the region
(termed “tagSNPs”), all common genetic variation present in
the population can be tested with very high coverage.
Genome-wide association studies (GWASs) are of indirect
design; they utilize LD by typically genotyping ~500,000–
1,000,000 SNPs that tag a large proportion of the roughly 10
million common SNPs present in the human genome. Most
CGASs of endometriosis have been of direct design (i.e., a
limited number of specific genetic variants were genotyped
and tested for association, although indirect tag approaches
have also been used [20]). For a detailed review of the design
of CGASs and GWASs and their underlying principles, see
Zondervan & Cardon [21].
We previously published a review of CGASs published
up to April 1, 2008 [20]. For this paper, we identified
CGASs of endometriosis published from April 1, 2008 to
April 1, 2012, conducting a systematic literature search in
Curr Obstet Gynecol Rep (2012) 1:124–137 125PubMed for English language publications, using the terms
“endometriosis” with “genetics” or “genes” or “polymor-
phisms.” An overview of these recent CGASs is presented
in Table 1. Variants from 73 candidate genes were tested
(Table 1), involved in sex steroid biosynthesis and signaling
pathways, adhesion molecules and matrix enzymes, immu-
nological mechanisms, inflammatory pathways, estradiol
metabolism, growth factor systems, cell cycle regulation,
oncogenes, apoptosis, and angiogenic factors [22].
For evidence of association to be credible, it is paramount
that the observed associations should be replicated in an inde-
pendent sample from the same underlying ethnic population
[21, 23]. Generally, many reported associations do not show
significant association in independent studies. This can be due
to many factors, such as differences in disease definition,
inadequate control selection, low coverage of the candidate
genes, small sample size of the initial dataset (creating a false-
positive result) or of the replication dataset (creating a false-
negative result), or population differences between the discov-
ery and the replication datasets. Moreover, to avoid failure to
replicate due to Winner’s curse (the statistical phenomenon in
which the effect size [the odds ratio] of the association in the
discovery dataset is larger than in any subsequent replication
dataset), the replication studies need to belarger in sample size
and have greater power than the discovery study to detect the
effect of the putative association [24].
As can be seen from the results in Table 1, no candidate
gene has been robustly associated with endometriosis across
studies. One of the most frequently investigated and plausi-
ble genes, encoding for vascular endothelial growth factor
(VEGF), probably shows the most suggestive evidence of
association. A literature-based meta-analysis of five poly-
morphisms from 11 studies including 1785 cases and 1879
control patients of Chinese, Indian, Korean, Japanese, Span-
ish, Turkish, Estonian, and Australian origin suggested one
significantly associated polymorphism (+936T/C; TT+TC
vs CC: P00.02) [25￿], although no such association was
found in a large study of 958 Australian cases and 959
control patients (P00.31) [26￿]. Similarly, our previous
review of 76 studies published until April 1, 2008 concluded
that none provided clear support for any genetic variant to
be robustly associated with endometriosis, and that some
reported results may represent true associations, but that
given the small effect sizes expected, large replication data-
sets or meta-analyses are required. In a large GWAS of
3,194 cases and 7,060 control patients of European ancestry,
all candidate genes from the 2008 Montgomery et al. review
[20] were investigated for nominal evidence of association
[27￿]; the only gene with a nominal P<10
−3 for SNPs in the
GWAS data was the gene encoding the progesterone recep-
tor (PGR) on chromosome 11, but the result for the SNP in
this gene was not significant in the replication stage. This
does not necessarily mean that none of these candidate
genes are involved in the causation of (subtypes) of en-
dometriosis; it also could mean that even in a large study
of all types of endometriosis, power is lacking to detect
their effect.
As can be seen in Table 1, the recent CGASs were
conducted in ethnically diverse populations. Because differ-
ent populations may have different genetic contributions to a
disease, and LD patterns may vary between ethnic popula-
tions, a genetic variant identified as causal in one population
may not be acting as a susceptibility variant in another.
Therefore, care should be taking in interpreting and com-
paring findings in terms of “replication.”
Hypothesis-Free Research: Whole Genome Linkage
Studies and Their Follow-up
One of the two hypothesis-free approaches to investigate
underlying genetic etiology of a disease is linkage mapping,
which adopts genetic investigation of families with multiple
affected individuals. This methodology became popular in
the 1980s after the discovery of highly variable genetic
markers (“microsatellites”), and works by 1) genotyping
about 400 microsatellites across the genome; 2) comparing
whether the allelic status of these variants are shared be-
tween affected people in a family; 3) summing this evidence
of sharing across multiple families; 4) calculating whether
the amount of sharing is more than expected by chance
based on simple Mendelian laws of inheritance; and 5)
identifying those genomic regions where excess sharing is
statistically significant. The linkage approach was highly
successful in identifying genetic variants responsible for
rare, monogenic disorders. Such disorders show clear Men-
delian segregation patterns through families [28, 29], and
the presence of the causal genetic variant determines wheth-
er or not the disease in question will develop. The genetic
causes of many of these monogenic diseases could be
‘mapped’ by investigating a handful of extended families
with many affected members.
Mendelian disorders are very different from complex
diseases such as endometriosis, in which one genetic variant
only carries susceptibility to disease (not 100 % risk). Many
more families with multiple affected women are required to
conduct a linkage study of endometriosis. Linkage studies
are fundamentally different from association studies; the
two approaches are complementary. In contrast to associa-
tion studies, which focus on SNPs common in the general
population, linkage studies are designed to detect disease-
causing variants responsible for disease in a family, but that
are otherwise rare in the general population. Moreover,
because linkage studies use recombination events in fami-
lies, the resolution of the approach is very large compared to
association studies: a significantly linked region typically
126 Curr Obstet Gynecol Rep (2012) 1:124–137Table 1 Candidate gene association studies of endometriosis published from April 2008 to April 2012, and total evidence for these from all studies
published until 2012
Candidate gene
** Chr Number of studies with association 2008–2012
*
Significant
(n cases, n controls)
Nonsignificant
(n cases, n controls)
#Sign/Total
up to 2012, n/n
***
Adhesion molecules and matrix enzymes
CDH1 16q22 Indian (715, 500) [73] – 2/2
Japanese (511, 498) [74]
ICAM1 19p13 Iranian (84, 120) [75] Korean (390, 351) [76] 2/5
MMP2 16q12 Estonian (150, 199) [77] – 2/3
MMP9 20q11-13 Estonian (150, 199) [77] – 1/2
MUC2 11p15 Taiwainese (195, 196) [78] – 1/1
MUC4 3q29 Taiwainese (140, 150) [79] – 1/1
Apoptosis, cell-cycle, DNA repair, and oncogenes
AKT1 14q32 – Indian (30, 30) [80] 0/1
APE1 14q11-12 – Turkish (52, 101) [81] 0/1
CDKN1A 6p21 – Taiwainese (180, 330) [82] 0/2
CDKN1B 12p13 Brazilian (104, 109) [83] – 1/1
HOGG1 3p26 – Turkish (52, 101) [81] 0/1
PI3KCA 3q26 – Indian (30, 30) [80] 0/1
TP53 17p13 Mexican (151, 204) [84] Brazilian (19, 19) [86] 4/9
Caucasian, Asian (749, 857)
a [85￿],
Taiwainese (180, 330) [82]
XPD 19q13 – Turkish (52, 101) [81] 0/1
XPG 13q33 – Turkish (52, 101) [81] 0/1
XRCC1 19q13 – Turkish (52, 101) [81] 0/1
XRCC3 14q32 – Turkish (52, 101) [81] 0/1
Cytokines/inflammation
C3 19p13 Puerto Rican (214, 147) [87] – 1/1
CTLA4 2q33 – Brazilian (177, 172) [88] 0/2
DR4/5 8p21 – Korean (138, 214) [89] 0/1
FCRL3 1q21-22 Brazilian (167, 167) [90] – 0/1
IFNG 12q24 Korean (622, 442) [91] – 3/3
Indian (302, 324) [92]
IL10 1q31-32 Danish (100, 358) [93] – 5/6
Taiwainese (196, 397) [94]
Chinese (214, 160) [95]
IL16 15q26 Chinese (230, 203) [96] – 1/1
IL18 11q22 Turkish (135, 84) [97] – 1/2
IL1B 2q13-21 – Turkish (118, 78) [98] 0/4
Taiwainese (196, 397) [94]
IL2RB 22q13 – Korean (237, 164) [99] 1/2
IL6 7p21-15 – Taiwainese (196, 397) [94] 0/5
Korean (390, 351) [76]
LOXL4 10q24 Puerto Rican (214, 147) [87] – 1/1
NFKB1 4q24 Chinese (206, 365) [100] – 1/1
PTGS2 1q25 – Taiwainese (196, 397) [94] 0/1
PTPN22 1q13 Brazilian (140,180) [101] Caucasian (789, 351) [103] 3/4
Polish (171, 310) [102]
TCRB 7q34 – Italian (70, 120) [104] 0/1
TNFA 6p21 Indian (245, 85) [105] Korean (105, 101) [106] 1/2
TNFR1 12p13 – Korean (105, 101) [106] 0/1
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Candidate gene
** Chr Number of studies with association 2008–2012
*
Significant
(n cases, n controls)
Nonsignificant
(n cases, n controls)
#Sign/Total
up to 2012, n/n
***
TNFR2 1p36 – Korean (105, 101) [106] 0/2
TNFRSF11B 8q24 – Korean (138, 214) [89] 0/1
TNFSF13B 13q32-34 Dutch (87, 107) [107] – 1/1
TRAIL 8p22-21 – Korean (138, 214) [89] 0/1
Estradiol metabolism
COMT 22q11 – Brazilian (198, 168) [108] 0/5
Caucasian (256, 567) [109]
HSD17B1 17q11-21 Estonian (150, 199) [110] Caucasian (256, 567) [109] 3/4
HSD17B2 16q24 – Caucasian (256, 567) [109] 0/1
Growth factor systems
BNC2 9p22.2 – Caucasian (789, 351) [111] 0/1
FGF1 5q31 – Chinese (421, 421) [112] 0/1
FGF2 4q26 Chinese (421, 421) [112] – 1/1
IGF1 12q23 – Korean (128, 108) [113] 0/1
IGF1R 15q26 – Korean (128, 108) [113] 0/1
IGF2 11p15 Korean (128, 108) [113] – 1/1
TGFB1 19q13 – Korean (485, 352) [114] 1/4
Korean (131, 107) [115]
VEGF 6p21-12 Turkish (98, 94) [116] Australian (958, 959)
c [26￿] 10/12
Chinese (344, 360) [117]
Caucasian (186, 180) [118]






ESR1 6q24-27 Chinese (214, 160) [95] Caucasian (256, 567) [109] 7/12
Estonian (150, 199) [110]
ESR2 14q21-22 Brazilian (108, 210) [119] Caucasian (256, 567) [109] 4/6
Brazilian (136, 209) [120]
Estonian (150, 199) [110]
PGR 11q22-23 Caucasian (348, 5820)
d [121￿] Caucasian (256, 567) [109] 6/9
Human leukocyte antigen system and immune components
CCL21 9p13 Caucasian (789, 351) [103] – 1/1
CD40 20q12-13 – Caucasian (789, 351) [103] 0/1
HLA region 6p21 – Japanese (89, 136) [122] 0/1
HLA-DRB1 6p21 Caucasian (789, 351) [103] – 1/2
IRF5 7q32 – Caucasian (789, 351) [103] 0/1
STAT4 2q32 – Caucasian (789, 351) [103] 0/1
TRAF1-C5 9q33-34 – Caucasian (789, 351) [103] 0/1
VDR 12q13 – Brazilian (132, 195) [123] 0/1
Other enzymes and metabolic systems
eNOS 7q36 Korean (299, 459) [124] Indian (232, 210) [125] 2/4
IRS2 13q34 Turkish (135, 135) [126] – 1/1
LHB 19q13 Brazilian (110, 209) [127] – 1/3
SERPINE 7q21-22 Brazilian (140, 148) [128] Italian (368, 329) [129] 2/3
Steroid-synthesizing enzymes, detoxifying enzymes, and receptors
CYP17A1 10q24 Turkish (46, 39) [130] Caucasian (256, 567) [109] 1/9
128 Curr Obstet Gynecol Rep (2012) 1:124–137extends across 10–50 Mb and contains hundreds of genes, in
contrast to the high resolution of association studies which
(depending on the local LD structure) are able to pinpoint a
signal to within 10–500 Kb.
The largest genome linkage scan to date was conducted by
the InternationalEndogeneStudy (consistingof 1,176affected
sib-pairs from Australian and United Kingdom families),
which identified a region of significant linkage on chromo-
some 10q26 [30]. In a subsequent analysis involving a subset
of 248 families with 3 or more affected members, a second
regionwasfoundonchromosome7p13-15likelyduetooneor
more rare variants following near-Mendelian patterns of inher-
itance [31]. In a recent study, the linkagepeakonchromosome
10q26regionwasextensivelygenotypedusing11,984SNPsin
1,144 familial cases and 1,190 control patients. The study
identified three independent signals in the region, at
96.59 Mb (rs11592737), 105.63 Mb (rs1253130), and
124.25 Mb (rs2250804), with nominally significant evidence
of association. However, only rs11592737 in the cytochrome
P450 subfamily C (CYP2C19) gene replicated (P00.04) in an
independent sample of 2,079 cases and 7,060 control patients
[32￿]. CYP2C19 is a plausible candidate for endometriosis
because it is involved in the metabolism of drugs and E
i n c l u d i n gc o n v e r s i o no fE 2t oe s t r o n e( E 1 ) ,a n dt h ep r o d u c -
tion of E1 and E2 2a- and 16a-hydroxylation metabolites
[33, 34]. Future studies should follow up by investigating
novel rare genetic variants in this region and conducting gene
expressionanalyses tofurtherunderstand the role ofCYP2C19
in endometriosis.
As a first approach to follow-up the significant linkage
peak on chromosome 7 region, the coding regions and up-
stream regulatory regions of three promising candidate genes
(INHBA, SFRP4,a n dHOXA10 with known roles in endome-
trial development)locatedwithinorclose tothelinkagesignal
were sequenced to identify potential causal polymorphisms.
Sequencing, rather than genotyping, was chosen because the
signal was likely due to one or more novel rare variants not
present on any genotyping array. Sequencing was conducted
in 47 cases from the 15 families contributing most to the
linkage signal, and 11 variants were found. The minor allele
frequencies (MAFs)ofobservedvariantswerecomparedwith
MAFs from two publicly available reference populations of
European ancestry: 60 individuals in HapMap and 150 indi-
viduals in the 1000 Genomes Project. Five of the 11 variants
were common (MAF>0.05); the remaining six variants were
rare and unlikely to be individually or cumulatively responsi-
ble for the linkage signal. These results indicate that the
coding regions of these three genes do not harbor rare muta-
tionsresponsibleforlinkagetoendometriosisinthesefamilies
[35]. However, this does not exclude the possibility that
Table 1 (continued)
Candidate gene
** Chr Number of studies with association 2008–2012
*
Significant
(n cases, n controls)
Nonsignificant
(n cases, n controls)
#Sign/Total
up to 2012, n/n
***
Italian (104, 86) [131]
CYP19A1 15q21 Caucasian (256, 567) [109] – 4/6
Italian (104, 86) [131]
CYP1A1 15q24 – Caucasian (256, 567) [109] 1/7
CYP1A2 15q24 – Caucasian (256, 567) [109] 0/1
CYP2C19 10q24 Turkish (50, 50) [132] Turkish (46, 39) [130] 1/2
GSTM1 1p13 Iranian (120, 200) [133] – 7/13
GSTP1 11q13 – Korean (260, 164) [134] 1/3
PPARG 3p25 Korean (446, 427) [135] – 3/3
Chr chromosome
*When more than one polymorphism was investigated in a study, the result is indicated as significant if one or more of the variants were reported as
significant by the authors.
** Candidate gene categories are as suggested by Falconer et al. [22].
*** Total number of candidate studies is summed
together with data from our review in 2008 [20]
aLiterature-based meta-analysis of P53 codon 72 polymorphism from six published studies of Asian and Caucasian ancestry. The study showed
significant association of the polymorphism with endometriosis only in the Asian patients [85￿]
bLiterature-based meta-analysis of five polymorphisms in the VEGF gene from 11 studies from Chinese, Indian, Korean, Japanese, Spanish, Turkish,
Estonian, and Australian patients. The study identified one significant polymorphism with endometriosis from the overall meta-analysis [25￿]
cGenotyped and tested the association of four VEGF polymorphisms with endometriosis in a large Australian sample. Then, performed a meta-
analysis with four additional published studies and showed no evidence for association neither in the genotyped association analysis they have
performed, nor in the meta-analysis for any of the four VEGF polymorphisms [26￿]
dAn international ovarian cancer consortium, including eight ovarian cancer case-controls studies from Australia, Europe, and the United States,
investigated the association of polymorphisms in PGR with endometriosis in 348 endometriosis patients and 5812 control patients [121￿]
Curr Obstet Gynecol Rep (2012) 1:124–137 129variants responsible for the linkage signal exist in noncoding
regions of these three genes, or that they are located in other
genes in this region.
Hypothesis-Free Research: Genome-wide Association
Studies
GWASs are based on the premise that common diseases such
as endometriosis are caused by genetic variants that are com-
mon themselves (Common disease-common variant hypoth-
esis [CDCV]). The first and seminal papers using GWAS
methodology successfully were published in 2005–2007
[36–38], and since then the method has taken off, resulting
in the detection of many common genetic variants associated
with complex diseases. The NHGRI (National Human Ge-
nome Research Institute) GWA Catalog (www.genome.gov/
GWAStudies)[ 39] counted the number of published signifi-
cant genome-wide associations (P≤5×10
−8)u pt oJ u n e2 0 1 1
at 1,449 for 237 traits. Key developments that enabled
GWASs were(1) the documentation ofhundredsofthousands
of common SNPs, and the LD patterns between them in
different populations in the human genome by the HapMap
Consortium [19]; and 2) the development of high-throughput
genomics platforms capable of genotyping over 1 million
SNPs in one assay at ever decreasing cost.
The first GWASs of endometriosis were published in
2010 and 2011: two in women of Japanese ancestry [40￿,
41] and one in women of European ancestry [27￿]. Only two
[27￿, 40￿] reported genome-wide significant signals, which
were replicated (Table 2). The first Japanese endometriosis
GWAS included 1,423 cases and 1,318 control patients in
the discovery sample, with cases a mixture of surgically
confirmed and clinically diagnosed women. After the appli-
cation of SNP quality control criteria, 460,945 SNPs were
included in the discovery analysis. A replication analysis
was conducted in an independent set of 484 cases and 3,974
control patients, in which the top 100 most significant SNPs
from the discovery set were genotyped. A significant asso-
ciation for one SNP was found, rs10965235, in CDKN2BAS
on chromosome 9p21 (P06.79×10
−6, odds ratio (OR)01.56
[1.29–1.89], P04.89×10
−4). Combining the discovery
and replication samples provided a genome-wide significant
result for rs10965235 (P05.57×10
−12,O R 01.44
[1.30–1.59]). Rs10965235 is located in intron 6 of
CDKN2BAS, which encodes for the cyclin-dependent kinase
inhibitor 2B antisense RNA (discussed further in this arti-
cle). Uno et al. [40￿] observed a second interesting potential
association with rs16826658, only providing suggestive
evidence, on chromosome 1p36 in a region close to WNT4
(combined datasets: P01.66×10
−6,O R 01.20 [1.11–1.29]).
WNT4 encodes for wingless-type MMTV integration site
family, member 4. Both these variants on chromosome
9p21 and 1p36 are novel susceptibility loci for endometri-
osis in the Japanese population [40￿], and are discussed
further in this article.
A second, independent, Japanese GWAS was published
recently, comprising a meta-analysis of two GWAS on two
case–control datasets. After quality control, 282,828 SNPs
were tested for association in 696 endometriosis cases (not
all surgically confirmed) and 825 control patients. Limited
by their sample size, their aim was to detect potential com-
mon susceptibility loci with large effect on the disease. The
study did not reveal any significant susceptibility loci for
endometriosis, which is likely to be due to the small sample
size of their dataset [41].
Table 2 Summary of significant genetic variants discovered by GWASs of endometriosis
Study Novel loci Top associated
SNP
Position Chr Population Sample size
(Ca:Co), n:n
Rep Biological explanation
Uno et al. [40￿] CDKN2BAS rs10965235 Genic 9 Japanese 1,423: 1,318 Yes Silencing of tumor suppressor
gene, CDKN2A,b y
CDKN2BAS may have an
important role in the
development of endometriosis
Painter et al. [27￿]
and Uno et al. [40￿]
WNT4 rs16826658 Genic 1 Japanese 1,423: 1,318 Yes Plays a role in development of




Painter et al. [27￿] mir-148a, NFE2L3,
HOXA11
rs12700667 Intergenic 7 Caucasian 3,194: 7,060 Yes Variant associated with WHR as
a measure of fat distribution.
Fat distribution is also
hormonally regulated;
suggestive pleiotropic locus
GWAS genome-wide association studies; SNP single nucleotide polymorphism; Ch chromosome; Ca cases; Co controls; Rep replication; WHR
Waist to hip ratio; Ref reference
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in women of European ancestry by the International EndoGene
Consortium (IEC) [27￿]. The study involved 3,194 surgically
confirmed endometriosis cases and 7,060 control patients from
Australia and the United Kingdom. Disease severity was
assessed retrospectively from surgical records using the rAFS
classification system and grouped into two phenotypes: stage A
(stage I or II disease or some ovarian disease with a few
adhesions; n01,686, 52.7 %) or stage B (stage III or IV
disease;n01,364,42.7%),orunknown(n0144,4.6%).After
qualitycontrol,analyseswereperformedusing504,723SNPs.
Analyzing all SNPs combined, Painter et al. [27￿]s h o w e da
significantly increased genetic loading among 1,364 cases
with stage B endometriosis compared to 1,666 with stage A
disease (proportion of endometriosis variation explained by
common SNPs: 0.34 [SD: 0.04] vs 0.15 [SD: 0.15] respec-
tively; P01.8×10
−3). Because of this result, two GWA anal-
yses were performed, using (1) 3,194 “all” endometriosis
cases and (2) 1,364 stage B cases. For “all” endometriosis,
the strongest signal observed was rs12700667 in an intergenic
region on chromosome 7p15.2 (P02.6×10
−7,O R 01.22
[1.13–1.32]), which was considerably stronger when limiting
cases to those with stage B endometriosis (P01.5×10
−9,
OR01.38 [1.24–1.53]). A second strong association was
found for rs1250248 (2q35) within FN1 (P03.2×10
−8). In
the replication phase, 70 SNPs that produced nominal evi-
denceofassociationwith “all”orstageBweregenotypedinan
independent dataset comprising 2,392 self-reported surgically
confirmed cases and 2,271 control patients from the Nurses’
Health Study I and II in the USA. The association on 7p15.2
with rs12700667 was replicated (P01.2×10
−3,O R 01.17
[1.06–1.28]). However, there was no evidence for replication
of rs12540248 (FN1) or association with the remaining SNPs.
Combined analysis of all 5,586 cases and 9,331 control
patients from Australian, UK and US datasets further con-
firmed association between “all” endometriosis and 7p15.2
(rs12700667,P01.4×10
−9,OR01.20[1.13–1.27]).Ofnoteis
that the estimated percentage of “all” endometriosis variance
explained by rs12700667 was only 0.69 % of the estimated
51 % heritability. Rs12700667 is located in a roughly 924-kb
intergenic region containing at least one noncoding RNA
(AK057379), predicted transcripts and regulatory elements,
and a micro RNA (miRNA [hsa-mir-148a]) about 88 kb up-
stream (discussed further in this article).
Painter et al. [27￿] also investigated the associations reported
by Uno et al. [40￿] in Japanese women. They found no evi-
dence for association with rs10965235 on chromosome 9p21
(rs10965235 is monomorphic in individuals of European de-
scent, reflecting the different genetic (ancestral) backgrounds
between the studies), nor with any SNPs in LD with
rs10965235. However, there was evidence for replication of
rs7521902 on 1p36, close to WNT4 gene, with the strongest
signal for stage B endometriosis (P07.5×10
−6,O R 01.25,
95 % CI 1.13–1.38); meta-analysis of the evidence from
“any” endometriosis (as severity of disease was not assessed
in the Japanese GWAS) combining the three GWAS datasets
resulted in a genome-wide significant P value of 4.2×10
−8
(OR01.19, 95 % CI 1.12–1.27).
GWASs for endometriosis, to date, have been conducted
on samples of relatively modest sizes compared to other
conditions, but these first studies have shown that there are
no common variants with large effects. ORs for replicated,
genome-wide significant signals are all lower than 1.5, an
observation that mirrors results from the many GWAS per-
formed on complex diseases to date. The results from Painter
et al. [27￿] suggest that future larger studies enriched for
surgically confirmed rAFS stage III/IV cases will be better
powered to identify risk loci of endometriosis, but further
work, requiring larger samples, needs to be conducted to
assess whether specific severe subtypes such as deep infil-
trating endometriosis [42] or rectovaginal disease [43] are
genetically heterogeneous from each other, or indeed if rAFS
stage III/IV is genetically heterogenous with respect to pres-
ence of endometriomas or scarring/adhesions. Furthermore,
the implicated variants from GWASs are likely to be in LD
with the actual disease-causing variants, and further in-depth
work to explore genetic variation in the regions, as well as
their influence on gene expression and downstream biolog-
ical pathways, now needs to be conducted. The variants
themselves are of small effect and explain only a very small
proportion of disease prevalence; hence, they are unsuitable
individually to serve as diagnostic markers. However, they
provide important data to define the underlying pathways
contributing to the disease, can be used to define genetically
heterogeneous subtypes that are likely to respond differently
to treatments, and thus, through the identification of differ-
ential pathways, help in the development of diagnostic tests
and future treatments.
Genes Implicated by GWAS of Endometriosis to Date
Although there was no evidence of a signal in women of
European ancestry [27], the GWAS by Uno et al. [40￿]c l e a r l y
implicated CDKN2BAS as potentially involved in endometri-
osisinJapanesewomen(Table2). CDKN2BASisan interesting
candidate because it is expressed in the uterus and regulates the
expressionof CDKN2B(p15), CDKN2A(p16), and ARF(p14),
which are tumor suppressor genes [44–46]. CDKN2A is a cell-
cycle–dependent kinase inhibitor and acts as a negative cell-
cycle regulator [47, 48]. Inactivation of CDKN2A has been
reported in a subset of endometrial carcinomas [49–52]. More-
over, hypermethylation of the CDKN2A promoter region has
beenobservedinendometriosis[52], andlossofheterozygosity
on the CDKN2A locus has been found in endometriosis, sug-
gesting that CDKN2A might play a role in the regulation of
endometrial cell growth [53]. The evidence from the literature
Curr Obstet Gynecol Rep (2012) 1:124–137 131suggests that silencing of tumor suppressor genes such as
CDKN2A by CDKN2BAS might have an important role in the
development of endometriosis [53].
The second novel genetic variant, which was supported by
evidence from GWASs in both women of Japanese and Euro-
pean ancestry, is located near WNT4, with evidence from the
latter mainly limited to rAFS stage III/IV disease. WNT4 is
known to play an important role in the development of the
female genital tract from the Müllerian duct that develops into
the fallopian tubes and uterus; the loss of WNT4 in knockout
mice was shown to lead to complete absence of the Müllerian
duct [54, 55]. Moreover, WNT4 is expressed in normal perito-
neum, suggesting that endometriosis may arise through meta-
plasia using developmental pathways involved in the
development of the female genital tract [54]. Furthermore, it
is possible that genetic variants in WNT4 might contribute to
endometriosis susceptibility through abnormal cell growth
in female genital tract. With all the evidence from the liter-
ature, WNT4, through its prominent role in development of
the female reproductive tract [55], ovarian follicle develop-
ment, and steroidogenesis [56], might play a critical role in
development of endometriosis.
The third novel genetic variant found only in the GWASs of
women of European ancestry [27￿], rs12700667, is located in
an intergenic region on chromosome 7p15.2. This locus was
not reported among the top 100 signals in the Japanese GWAS
by Uno et al. [40￿]; however, given their sample size they
would have had only 13 % power to detect it [27￿]. Chromo-
some 7p15.2 contains multiple genomic features that may be
involved in endometriosis development. The region contains a
number of expressed sequence tags (ESTs) and a miRNA
(has-mir-148a), suggesting a role in gene expression regula-
tion. Further downstream, there are several genes including
NFE2L3 (highly expressed in placenta) and two endometriosis
candidate genes, HOXA10 and HOXA11, which are transcrip-
tion factors that play a role in uterine development. Another
interesting aspect about this variant comes from a large GWAS
(n077,167) investigating the genetic variants associated with
fat distribution as measured by waist-to-hip ratio adjusted for
the effect of body mass index (WHRadjBMI) [57]. Interesting-
ly, rs12700667 is positioned at the same locus as one of 13
genome-wide significant loci they reported as associated with
reduced WHRadjBMI, a result that is currently further being
explored. As endometriosis and fat distribution are both hor-
monallydependent,pleiotropicgeneticlociactingonbothtraits
may well exist.
Challenges and Future Directions
The first GWASs of endometriosis have identified three
genetic loci highly likely to be involved in the pathogenesis
of endometriosis in women of Japanese and European
ancestry. Although they have identified the loci, they have
not pinpointed the actual genetic variants that are causal to
endometriosis. Furthermore, they explain only a fraction of
the heritability of endometriosis. Therefore, directions for
further investigation include the following:
(1) The GWASs of endometriosis to date are relatively
crude, in that they generally only describe associations
with endometriosis, without regard for subtypes or
differences in symptomatology (pain and infertility).
Only the IEC GWAS [27￿] considered stage B versus
stage A endometriosis, showing that the two are genet-
ically different in etiology. Future studies need to in-
clude cases who are phenotyped in much greater detail
to enable distinction between endometriosis subtypes.
For these studies to have sufficient power, however,
even larger sample sizes are required than used to date.
(2) Of the 1,449 novel loci identified by GWASs up to June
2011 [39], the number of loci identified per complex trait
varies greatly. Visscher et al. [58] showed that the number
of discovered variants is strongly correlated with the
sample size of different studies. The sample sizes of the
endometriosis GWASs are at the lower end of those that
have been successful in identifying loci involved in the
etiology of a complex trait. This means that increasing the
discovery sample size will increase the number of discov-
ered variants, which also was suggested by prediction
analyses based on all genotyped SNPs in the GWAS of
the IEC [27￿]. When individual causal variants only ex-
plain a small amount of variation, then the power to detect
them is low in studies with small sample sizes. Therefore,
there is a need for larger endometriosis GWASs in differ-
ent populations, and meta-analyses of GWASs, to detect
additional common causal variants with modest effect on
risk. As mentioned before, the power of these studies can
be increased by focusing on more severe subtypes, and in
general by ensuring detailed and accurate clinical pheno-
typing allowing the investigation of such subtypes.
(3) To maximize information gained from GWASs, dense
genotyping platforms containing at least 500,000 SNPs
selected on the basis of LD should be utilized in GWASs,
and imputation approaches should be used to estimate
non-genotyped common variants (eg, using 1000
Genomes project data [http://www.1000genomes.org]).
To follow up on initial GWA scans and to further improve
the coverage,custom-made genearrays could be designed
including dense SNP sets focused on implicated genes
(although, if budget allows, sequencing of these may be
preferable); these could be supplemented by genes
robustly implicated in hypothesized related common dis-
ease such as gynecological cancers [59, 60], migraine
[61] or complex traits such as age of menarche [62]a n d
body mass index (BMI) [63]. The use of whole exome
132 Curr Obstet Gynecol Rep (2012) 1:124–137genotyping arrays, including carefully selected sets of
commonandlow-frequency variantsin exons,alsocould
be a promising approach to identify additional signals.
(4) Although GWASs are unbiased by prior biological
knowledge or genomic location, they are limited with
regardtotheirabilitytoonlyassesstheeffectofcommon
SNPs (MAF>~0.05) in the general population. It is
possible that some of the unexplained genetic variation
may be due to rarer variants (MAF<0.5 %), either
single-site or structural, that are not captured by current
GWA genotyping arrays [64, 65]. Indeed, the effects of
structural variation are generally missed out in GWAS
(although some of the GWA arrays contain selected
probes to test for common copy number variation
[CNV]). Rare and structural variants can be investigated
through exome or whole-genome sequencing; however,
these studies are still challenging because of their cost,
with bioinformatic methodology to accurately call struc-
tural variants in particular still under development.
(5) Preliminary studies have suggested the role of gene–
gene and gene–environment interactions in the devel-
opment of endometriosis [66, 67]. There is no doubt
that such interactions play a role in the development of
many complex traits, but to robustly ascertain them
without strong prior hypotheses, even larger sample
sizes are generally required than advocated for GWAS.
A biological route through which environmental fac-
tors could impact on the influence of genes on disease
is through epigenetic modification of DNA (mainly
methylation). There is considerable interest in epige-
netic variants as contributors to the unexplained genet-
ic variation of endometriosis [68]. One method through
which the role of epigenetic variants in the develop-
ment of endometriosis could be tested is by using a
twin cohort where age-specific endometriosis concor-
dance rates are obtained from monozygotic and dizy-
gotic twins. If the monozygotic twin concordance rates
for endometriosis increase with age, this could provide
evidence for the potential role of epigenetic factors
[69]. However, a major issue for endometriosis could
be age-specific confounding by patterns of diagnosis.
Platforms to detect genome-wide DNA methylation are
being developed, and although currently still based on
selected loci, are increasingly providing exciting new
avenues for exploring the effect of epigenetic changes
on complex disease such as endometriosis.
(6) Although the study of the genetics of endometriosis is
starting to reap fruits, it is still faced with many chal-
lenges inherent to the complexities of the disease. This
includes the general lack of correlation between disease
stage and pain severity; much greater phenotypic detail
of cases included in genetic studies is needed to start
distinguishing between potential subtypes of disease and
symptomatologies.Aparticularproblem istheneedfor a
surgical diagnosis, which hampers population-based re-
search. A complementary avenue may be to study the
disease in animal models, in particular nonhuman pri-
mates such as the rhesus macaque [70] or the baboon
[71, 72], with the rhesus macaque a promising model for
the study of heritable, spontaneously occurring endome-
triosis [17]. Work on the genetics of endometriosis in the
rhesus macaque, comparing human and rhesus macaque
genomes, is currently underway.
Conclusions
There is mounting evidence for genetic variants contributing
to endometriosis susceptibility. To date, candidate gene
studies have not provided robust, replicated genetic variants
associated with endometriosis and they have low a-priori
chance of success when based solely on biological hypoth-
eses. Linkage studies in pedigrees have found some regions
of interest, which are likely to harbor variants implicated in
familial endometriosis; however, due to the methodology,
the regions identified are large and contain many genes of
potential interest. These regions require further investiga-
tions to elucidate the susceptibility variants. The much-
anticipated initial GWAS results identified three regions
showing robust association with endometriosis in women
of Japanese and European ancestry. Although they are by far
the largest studies of endometriosis to date, they were of
relatively small sample size compared to GWASs of other
traits, and generally lacked detailed clinical information that
would have allowed investigation of more etiologically ho-
mogeneous subphenotypes of endometriosis. Such informa-
tion needs to be collected systematically for future analyses,
and well-designed and sufficiently powered GWASs of
thousands of cases and controls need to be conducted to
identify novel genetic variants associated with endometri-
osis. These larger studies also will allow for better investi-
gation of potential gene–gene and gene–environment
interactions. Moreover, there are upcoming opportunities
to study the impact of environment on genetic factors influ-
encing endometriosis, through epigenetic studies, with the
development of platforms to detect epigenetic changes
genome-wide. Identification of robust, replicated genetic/
epigenetic variants of endometriosis will pave the way to
functional studies to better understand the underlying mech-
anisms of endometriosis, leading to better diagnosis and
treatment of the disease. Complimentary research in animal
models, particularly nonhuman primate models such as the
rhesus macaque and the baboon, which can develop endo-
metriosis spontaneously, should help to further elucidate the
genetics of this complex condition.
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